BenevolentAI Investor Day Presentation Deck

Portfolio key inflection points BEN-2293 Atopic Dermatitis BEN-8744 Ulcerative Colitis H2 2022 BEN-28010 Glioblastoma multiforme Pipeline depth and progression Complete Phase lla clinical study File Clinical Trial Application (CTA) late 2022 Commence iND enabling studies Move at least 1 project into lead opt & Initiate 2 - 4 new drug discovery programmes 2023 Full data package available Q1 2023 Begin Phase I study early 2023 Submit Clinical Trial Application (CTA) Expect to add 4-6 names drug programmes 2024 Phase I data package early 2024, with Phase II to follow shortly after Initiate Phase I study Aim to progress 1-2 CTA/IND stage drug candidates every year Benevolent 64

View entire presentation